Evidence map›Paper›PMID 40064932›Full record

ArticleNature communications2025

Enzyme-activating B-cell receptors boost antigen presentation to pathogenic T cells in gluten-sensitive autoimmunity.

Rasmus Iversen, Julie Elisabeth Heggelund, Saykat Das, Lene S Høydahl, Ludvig M Sollid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rasmus Iversen *Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. rasmus.iversen@medisin.uio.no.ORCID http://orcid.org/0000-0002-3292-1766
Julie Elisabeth Heggelund *Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-7805-1754
Saykat DasNorwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lene S HøydahlNorwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-6070-1413
Ludvig M SollidNorwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. l.m.sollid@medisin.uio.no.ORCID http://orcid.org/0000-0001-8860-704X

Funding

LEO Pharma Research Foundation LF-OC-23-001291Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2020027Stiftelsen Kristian Gerhard Jebsen (Kristian Gerhard Jebsen Foundation) SKGJ-MED-017Universitetet i Oslo (University of Oslo) WL-IMMUNOLOGY
6 · The paper itself

Abstract

Autoantibodies against the enzyme transglutaminase 3 (TG3) are characteristic to the gluten-sensitive skin disorder dermatitis herpetiformis (DH), which is an extraintestinal manifestation of celiac disease. We here demonstrate that TG3-specific B cells can activate gluten-specific CD4

Indexed as

Antigen PresentationAutoimmunityCD4-Positive T-LymphocytesGlutensReceptors, Antigen, B-CellTransglutaminasesAnimalsAutoantibodiesB-LymphocytesCeliac DiseaseDermatitis HerpetiformisHumansMiceMice, Inbred C57BLT-LymphocytesAutoantibodiesGlutensReceptors, Antigen, B-CellTransglutaminases

Identifiers

PMID40064932
PMCPMC11894174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.